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CASE 1
REVIEWING THE REIMBURSEMENT STATUS OF
PHARMACEUTICALS—EXPERIENCES FROM SWEDEN
Engstrom A, Ramsberg J
Pharmaceutical Beneﬁts Board, Solna, Sweden
Organization: The Pharmaceutical Beneﬁts Board in Sweden
(LFN).
Problem or Issue Addressed: Uncertainty about the cost-
effectiveness of reimbursed products.
In Sweden, the Pharmaceutical Beneﬁts Board (LFN) was insti-
tuted in 2002 with the purpose of contributing to a rational and
cost-effective use of pharmaceuticals. The Board’s assignment is
to systematically and in accordance with national prioritization
guidelines decide which pharmaceuticals should be reimbursed.
Societal cost-effectiveness is a key decision parameter. One task
of the LFN is to review the subsidy status of all products (∼3000
products) that were already in the pharmaceutical beneﬁts when
the Board was instituted. Also these products should meet the
current requirements for cost-effectiveness.
Goals: These reviews serve two purposes. First and foremost, to
inform the Board’s decisions on subsidy status, second, to help
other decision makers in Swedish health care to use pharmaceu-
ticals rationally and cost-effectively. To meet both these objec-
tives, the reviews need to meet scientiﬁc standards and yet be
delivered in a timely fashion.
Outcomes Items used in the Decision: The scientiﬁc literature is
searched for systematic reviews and meta-analyses of effective-
ness and efﬁcacy data, evidence on the humanistic burden of
disease, as well as for health economic evaluations. If deemed
necessary, the LFN may perform additional health economic
analyses or modelling.
Implementation Strategy: The products have been classiﬁed into
49 groups (using three-digit ATC codes). A project team con-
sisting of a pharmacist/pharmacologist, a health economist and
a legal advisor is assembled for each review group. 3–4 external
clinical experts are also attached to the project group. These
experts are recruited based on nominations from stakeholders,
both from the health care system, patient groups and the phar-
maceutical industry. Companies marketing a product included in
a review are also asked to submit documentation about which
studies best support the effectiveness and cost-effectiveness of
their product. Before a report is published it is sent out for review
by the stakeholders involved.
Results: Two reviews have been completed so far (drugs against
migraine and acid related problems) and another six are cur-
rently in progress. The results from the review of drugs against
migraine resulted in one triptan being removed from reimburse-
ment and two manufacturers chose to lower their prices to make
their products cost-effective. Based on the review of drugs
against acid related problems the Board decided to remove two
proton pump inihibitors from reimbursement since they were
found not to be cost-effective compared to generic omeprazol.
H2-antagonists were removed from reimbursement based on
need and solidarity grounds. In addition to decisions to remove
individual products from reimbursement, recommendations on
cost-effective use of the pharmaceuticals were included in the
reports. The impact of such recommendations on clinical prac-
tice seems to be quite small according to the sales data.
Lessons Learned: Reviewing an entire group of pharmaceuticals
is time consuming especially in a small organization. It is
however possible to produce reports of a high quality which can
be used as a basis for decision making even with comparatively
limited resources by using existing systematic reviews and only
when necessary performing them within your own organization.
Substantial savings and better health outcomes are possible to
achieve if cost-effective strategies can be identiﬁed.
CASE 2
COST CONTROL FOR MENTAL HEALTH
Dubberly J1, Perri M2, Smith L1,Walthour A2
1The Georgia Department of Community Health, Atlanta, GA, USA,
2University of Georgia, Athens, GA, USA
Organization: The Georgia Department of Community Health
(DCH).
Problem or Issue Addressed: Rapidly rising costs of treating
mental illness in the Georgia Medicaid population
Goals: The Georgia Medicaid program has experienced rapidly
rising costs of treating mental illness. Along with this, clinical
studies have described the beneﬁts and risks of the various agents
used to treat mental illness. For this study, mental health drugs
included medications for: Attention Deﬁcit Hyperactive Disor-
der (ADHD), Selective Serotonin Reuptake Inhibitors (SSRI)
atypical antipsychotic agents and new generation antidepres-
sants. DCH sought to reduce the cost of treating mental illness
while maintaining quality of care provided to members. Cost
reduction was to be obtained by promoting the use of preferred
products in these categories through the traditional methods of
co-pay differentials (preferred and non-preferred agents), step
therapy protocols, as well as prior authorization.
Outcomes Items Used in the Decision Process: DCH utilized clin-
ical recommendations from the GA Drug Utilization Review
Board to deﬁne optimal therapy based on the clinical data. Clin-
ical input from practicing psychiatrists was also utilized to struc-
ture the program and exception criteria. Concerns raised by
national as well as local mental health advocacy organizations
also shaped the outcomes that were measured as part of this
effort. Costs were monitored by examining units of service, as
well as the total cost and numbers of prescriptions for central
nervous system medications for mental health patients. Hospital
admission rates, average length of hospital encounters, number
of emergency department visits, physician ofﬁce visits, as well as
loss of Medicaid eligibility due to incarceration were all included
in the outcome measures tracked.
Implementation Strategy: Prior to May 2004, all medications in
the therapeutic category were evaluated from a clinical perspec-
tive and recommendations made to DCH by the Drug Utiliza-
tion Review Board. Next, the net cost to the state, associated
with treatment with each agent was considered. Preferred and
Non preferred status was assigned to some agents, others were
included in step therapy protocols, and ﬁnally some agents were
only obtainable with prior authorization. Policy changes in drug
coverage were then phased in between May 1, 2004 and Novem-
ber 1, 2004 with all current users being grandfathered. The order
of implementation was ADHD, SSRI’s, Atypical Antipsychotic
agents and ﬁnally new generation antidepressants. Follow up to
monitor the outcomes measures (total payments, units of service,
the total cost and numbers of prescriptions for central nervous
system medications for mental health patients, hospital admis-
sion rates, average length of hospital encounters, emergency
department visits, physician ofﬁce visits, as well as loss of Med-
icaid eligibility due to incarceration) was conducted every three
months for two years following the policy changes.
